K.J. Harrison & Partners’s TriSalus Life Sciences TLSI Stock Holding History

K.J. Harrison & Partners’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-35,000	Closed	-$346K	–	374
2021 Q4	$346K	Sell	35,000 -45,000	-56%	-$447K	0.05%	225
2021 Q3	$799K	Sell	80,000 -60,000	-43%	-$587K	0.12%	172
2021 Q2	$1.36K	Hold	140,000	–	–	0.14%	134
2021 Q1	$1.35M	Buy	+140,000	New	+$1.42M	0.21%	130

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

K.J. Harrison & Partners's TLSI Position: Q1 2022 in Review

K.J. Harrison & Partners sold out of TriSalus Life Sciences (TLSI) in Q1 2022, closing a stake of 35,000 shares — an estimated $346K sold.

K.J. Harrison & Partners first reported a position in TLSI in Q1 2021 and held it in 4 quarters. The position peaked at $1.35M in Q1 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q1 2022.

K.J. Harrison & Partners reported no remaining TriSalus Life Sciences position as of Q1 2022 after selling out during the quarter.
K.J. Harrison & Partners sold 35,000 TriSalus Life Sciences shares in Q1 2022, an estimated $346K.
K.J. Harrison & Partners first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 4 quarters.
K.J. Harrison & Partners's TriSalus Life Sciences position peaked at $1.35M in Q1 2021.
68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2022.

Based on K.J. Harrison & Partners's 13F filing for Q1 2022, filed 21 Apr 2022.